Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CORRECTION: Innoviz Technologies Q3 EPS $(0.20) Misses $(0.15) Estimate, Sales $2.10M

Innoviz Technologies (NASDAQ:INVZ) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.15) by 33.33 percent. The company reported $2.10 million in sales this quarter.
byBill Haddad
November 10, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Innoviz Technologies (NASDAQ:INVZ) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.15) by 33.33 percent. The company reported $2.10 million in sales this quarter.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

MaxCyte Signed Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

By Charles Gross
December 5, 5:51 AM
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat

MXCT